Drug Type Bispecific antibody |
Synonyms DIG-KT |
Target |
Action antagonists |
Mechanism Tie-2 antagonists(TEK receptor tyrosine kinase antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | - | |
Neoplasms | Preclinical | - | - |